Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial

Naftali, Timna; Mechulam, Refael; Marii, Amir; Gabay, Gila; Stein, Assaf; Bronshtain, Miriam; Laish, Ido; Benjaminov, Fabiana; Konikoff, Fred M.

doi:10.1007/s10620-017-4540-z

Cited by 147 publications

(159 citation statements)

References 28 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…Within the RCTs, CBD did not significantly change the primary outcomes in diabetes ( n = 62), Crohn's disease ( n = 19), ocular hypertension ( n = 6), chronic pain (mostly neuropathic; n = 24), or fatty liver disease ( n = 25) . However, an average dose of 2.4 mg/kg/d (range 0.3–13.3 mg/kg/d) was used in these studies, which is very low in the clinical and clinical trial setting compared to other studies.…”

Section: Resultsmentioning

confidence: 86%

A systematic review of cannabidiol dosing in clinical populations

Millar

Stone

Bellman

et al. 2019

Brit J Clinical Pharma

160

148

View full text Add to dashboard Cite

Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in a wide‐variety of contexts; however, its effective dose in different disease states remains unclear. This review aimed to investigate what doses have been applied in clinical populations, in order to understand the active range of CBD in a variety of medical contexts. Methods Publications involving administration of CBD alone were collected by searching PubMed, EMBASE and ClinicalTrials.gov . Results A total of 1038 articles were retrieved, of which 35 studies met inclusion criteria covering 13 medical contexts. Twenty‐three studies reported a significant improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), with doses ranging between <1 and 50 mg/kg/d. Plasma concentrations were not provided in any publication. CBD was reported as well tolerated and epilepsy was the most frequently studied medical condition, with all 11 studies demonstrating positive effects of CBD on reducing seizure frequency or severity (average 15 mg/kg/d within randomised controlled trials). There was no signal of positive activity of CBD in small randomised controlled trials (range n = 6–62) assessing diabetes, Crohn's disease, ocular hypertension, fatty liver disease or chronic pain. However, low doses (average 2.4 mg/kg/d) were used in these studies. Conclusion This review highlights that CBD has a potential wide range of activity in several pathologies. Pharmacokinetic studies as well as conclusive phase III trials to elucidate effective plasma concentrations within medical contexts are severely lacking and highly encouraged.

show abstract

Section: Resultsmentioning

confidence: 86%

A systematic review of cannabidiol dosing in clinical populations

Millar

Stone

Bellman

et al. 2019

Brit J Clinical Pharma

160

148

View full text Add to dashboard Cite

show abstract

“…The results of the first clinical study of CDB for the treatment of inflammatory bowel have been published very recently. Unfortunately, the effects of CBD on Crohn’s disease were ineffective in a randomized placebo-controlled trial on 20 patients probably due to low used doses (Naftali et al, 2017). The potential antiepileptic effects of CBD in patients suffering seizures associated with Lennox–Gastaut syndrome and in children and young patients with Dravet syndrome are currently on-going.…”

Section: Resultsmentioning

confidence: 99%

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol

2017

View full text Add to dashboard Cite

Cannabidiol (CBD) has been traditionally used in Cannabis-based preparation, however historically, it has received far less interest as a single drug than the other components of Cannabis. Currently, CBD generates considerable interest due to its beneficial neuroprotective, antiepileptic, anxiolytic, antipsychotic, and anti-inflammatory properties. Therefore, the CBD scaffold becomes of increasing interest for medicinal chemists. This review provides an overview of the chemical structure of natural and synthetic CBD derivatives including the molecular targets associated with these compounds. A clear identification of their biological targets has been shown to be still very challenging.

show abstract

“…CBD has been preliminarily evaluated also in inflammatory bowel disease (IBD) patients. In Crohn's disease patients ( n = 20) who did not respond to standard treatment with steroids, a low dose of CBD displayed no beneficial effects (Naftali et al, ). On the other hand, although a CBD‐rich botanical extract (50 mg for 12 weeks) did not significantly affect the primary endpoint (i.e.…”

Section: Cannabidiolmentioning

confidence: 99%

Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals

Williamson

Liu

Izzo

2020

British J Pharmacology

201

173

View full text Add to dashboard Cite

The nutraceuticals market is vast, encompassing many different products with inconsistent levels of evidence available to support their use. This overview represents a Western perspective of the nutraceuticals market, with a brief comparison with that in China, as an illustration of how individual health supplements increase and decrease in popularity in regional terms. Recent changes in sales patterns, mainly taken from the US market, are summarized and a selection of five newer products, which have not been subject to extensive recent review are profiled: astaxanthin, a carotenoid found in red algae, seafood, salmon and trout, as an antioxidant; cannabidiol, a non‐euphoric marijuana ingredient used as mood enhancer and for painful/inflammatory conditions; modified extracts of ginseng used in new indications including dementia and space travel; monk fruit, a non‐sugar high intensity sweetener and nigella seed, a popular food ingredient and Asian medicine, which has experienced an extraordinary rise in sales recently. Linked Articles This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc

show abstract

Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial

Cited by 147 publications

References 28 publications

A systematic review of cannabidiol dosing in clinical populations

A systematic review of cannabidiol dosing in clinical populations

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol

Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals

Contact Info

Product

Resources

About